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Introduction
Streptococcus pneumoniae is a major cause of invasive 
(bacteremic pneumonia, meningitis, and septicemia) and non-
invasive (non bacteremic pneumonia and otitis media) human 
infectious diseases, with high worldwide annual rates of morbidity 
and mortality, particularly in children and the elderly.1,2 The 
incidence, prevalence, and mortality due to pneumococcal 
diseases vary widely, both in different countries and over time, 
likely in relation to improved knowledge and management of 
the related diseases, and principally to the implementation of 
universal vaccination campaigns on a national basis.3
In fact, vaccination remains the only public health strategy 
that, by reducing the incidence of the pneumococcal diseases, 
plays a major role in decreasing the global burden.4 Two types 
of vaccines are currently available worldwide: a pneumococcal 
conjugate vaccine (PCV), initially recommended for infant 
immunization, and a pure polysaccharide pneumococcal 
vaccine (PPV), recommended for adult immunization. Several 
international health authorities, including the Region of Sicily’s 
Health Commission, have recommended pneumococcal 
vaccination in both children and older adults as the best 
strategy for reducing the circulation of S. pneumoniae in these 
populations.5
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Streptococcus pneumoniae is a major cause of human infectious diseases worldwide. Despite this documented 
evidence, data on pneumococcal disease rates among general populations are scant because of the frequent lack of 
cultural identification. In this study we propose a model for estimating the burden of pneumococcal pneumonia on 
hospitalizations.
The study was performed by analyzing administrative and clinical data of patients aged 50 years or older, resident in 
sicily, and hospitalized, from 2005 to 2012. Demographic information, admission/discharge dates, discharge status, and 
up to 6 discharge diagnoses coded according to IcD-9 cM were collected for each hospitalized patient.
During the 8-year study period, a total of 72 372 hospitalizations with at least one IcD-9 cM diagnosis code suggestive 
of all-cause pneumonia were recorded. Of these, 1943 (2.7%) hospitalizations had specific IcD-9 cM diagnosis codes for 
pneumococcal pneumonia. according to the proposed model, 16 541 (22.9%) pneumonia out of all-cause pneumonia 
was estimated to be attributable to S. pneumoniae. Pneumococcal pneumonia and model-estimated pneumococcal 
pneumonia had mean hospitalization rates of 13.4 and 113.3/100 000, respectively, with a decreasing temporal trend. The 
risk of hospitalization for pneumococcal pneumonia was strongly correlated with age (P < 0.001). Our model provides data 
usable to construct suitable decisional models for the decision-makers and could allow to the responsibles of healthcare 
facilities to assess the budget impact if they hypothesize to offer vaccination for pneumococcal disease to certain cohorts 
of subjects aged 50 years or older. In our area, the high estimated hospitalization rates among adults aged ≥65 years 
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Following these recommendations, in Sicily PCV vaccination 
for children was introduced in the regional immunization 
program and actively offered from 2005, with very high 
coverage, resulting in a significant reduction in pneumococcal 
disease.6,7
PPV has been also been recommended for adults aged >65 
y and persons who have certain underlying medical conditions 
that may increase the risk of pneumococcal infection.8 However, 
despite these recommendations, PPV coverage in Sicily is 
currently extremely low among adults.
Furthermore, data on the burden of pneumococcal diseases 
are scant due to the frequent lack of cultural identification of 
the causal agent during the medical care of the disease. As a 
consequence, the etiologic fraction attributable to S. pneumoniae 
may be underestimated or, alternatively, overestimated, 
considering all potentially attributable pneumococcal diseases 
in the absence of microbiological identification.
In this study we propose the application of a model for estimating 
the burden of pneumococcal pneumonia on hospitalizations of 
patients aged 50 y or older and resident in Sicily.
Figure 1. IcD-9 cM codes for all-cause pneumonia recorded, as principal or secondary diagnosis, in a total of 72 372 hospitalizations for 























www.landesbioscience.com human Vaccines & Immunotherapeutics 3
Results
During the 8-y study period, a total of 72 372 hospitalizations 
with at least one ICD-9 CM diagnosis code suggestive of all-
cause pneumonia were reported in Sicily among adults aged 
≥50 y. Figure 1 shows the ICD-9 CM diagnosis codes for total 
episodes of hospitalizations for pneumococcal pneumonia in 
Sicilian patients.
Overall, 1943 (2.7%; 95% CI = 2.6–2.8%) hospitalizations 
had specific ICD-9 CM diagnosis codes for pneumococcal 
pneumonia. Pneumococcal pneumonia patients had a mean age 
of 73.3 ± 11.3 y and 60% (n = 1165) were male. The median 
length of in hospital stay was 9 d (interquartile range = 7).
In the same period, 6480 and 55 869 hospitalizations included 
ICD-9 CM codes for unspecified bacteria or unspecified cause, 
accounting for 9% (95% CI = 8.7–9.2%) and 77.2% (95% CI = 
76.9–77.5%) out of all-cause pneumonia, respectively. According 
to the proposed model, 1839 (28.4%; 95% CI = 27.3–29.5%) of 
the 6480 unspecified bacterial pneumonia and 12 759 (22.8%; 
95% CI = 22.5–23.2%) of the 55 869 unspecified pneumonia 
were estimated to be attributable to S. pneumoniae, accounting for 
a total of 16 541 (22.9%; 95% CI = 22.6–23.1%) hospitalizations.
Figure 2 depicts hospitalization rate trends of all-cause 
pneumonia, unspecified pneumonia, pneumococcal pneumonia 
and model-estimated pneumococcal pneumonia. All-cause 
pneumonia and unspecified pneumonia increased over time, 
with mean incidence rates of 497 and 383.4 cases/100 000, 
respectively. Otherwise, pneumococcal pneumonia and model-
estimated pneumococcal pneumonia had mean hospitalization 
rates of 13.4 and 113.3/100 000, respectively, with a decreasing 
temporal trend (chi-square test for trend = 42.8 and 124.1, 
respectively; P value < 0.001 in both cases).
Incidence rates of unspecified bacterial pneumonia and 
bacterial pneumonia (mean incidence rates of 44.5 and 47 
cases/100 000, respectively) were relatively constant over time 
(data not shown).
Table 1 shows hospitalization rates estimated for pneumococcal 
pneumonia by age and year of hospital admission. Annual 
hospitalization rates for pneumococcal pneumonia ranged from 
141.1 cases per 100 000 in 2005 (95% CI = 137.4 to 148.8) to 
95.9 cases per 100 000 in 2012 (95% CI = 91.5 to 100.4).
The risk of hospitalization for pneumococcal pneumonia was 
found to be strictly correlated with age (P < 0.001 by chi-square 
test for trend in all years), increasing about 15-fold from age class 
50–54 y to ≥80.
Discussion
In Italy there are no reliable sources of information on 
invasive pneumococcal pneumonia incidence since these 
infections are not included in the national notification system.9 
Hospital discharge databases, therefore, are the only source for 
a timely and inexpensive picture of the epidemiology of almost 
all severe diseases, as they provide a complete record of all 
hospitalizations, and include standardized diagnosis code lists 
that enable secular trend analysis of incident disease for a given 
population.
Figure 2. hospitalization rate trends of all-cause pneumonia, unspecified pneumonia, pneumococcal pneumonia, and model estimated pneumococcal 
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Despite these advantages, hospital discharge databases 
are subject to some limitations that are common to all passive 
surveillance systems, such as under-diagnosis or deficiencies in 
reporting. For infectious diseases, these problems are at least in 
part due to the frequent empirical clinical management of the 
diseases without an etiologic identification of the causative agent, 
which in Italy has been estimated to occur in more than two-
thirds of the hospitalizations for pneumonia.10
In view of this, several studies have reported that ICD-9 
CM codes suggestive of pneumococcal pneumonia have good 
specificity, but poor sensitivity.11,12 Very low sensitivity can 
be hypothesized in our area, as in others, considering that 
hospitalization for pneumococcal pneumonia represents less than 
3% of all-cause pneumonia, whereas previous studies performed 
in several European nations, including Italy, have reported that 
S. pneumoniae is usually implicated in 11.9% to 68.3% of adult 
community-acquired pneumonia.10
In order to control for underreporting, we designed a model 
that estimates a burden of hospitalizations for pneumococcal 
pneumonia in an age group that, during the study period, in Sicily 
has accounted for a large proportion of the general population, 
increasing from 34.6% in 2005 to 38% in 2012.
The model shows estimated morbidity rates more than 8-fold 
higher than that observed by analyzing specific ICD-9 CM 
codes. These estimates seem to be realistic for 2 reasons.
First, annual hospitalization rates estimated in Sicily for 
pneumococcal pneumonia are included in the same size range 
as that calculated in other Italian areas, where they ranged from 
62.9 cases per 100 000 persons aged 65–74 y to 422.7 per 100 000 
aged ≥85.13
Second, these estimates allow us to calculate that ICD-9 CM 
codes suggestive of pneumococcal pneumonia would have a 
sensitivity of 11.7%, which is similar to, but conservatively higher 
than, the 8% observed in other Italian studies.14 Both these values 
underline that up to 90% of pneumococcal pneumonia cases may 
remain undetected, and are also consistent with the finding that 
in Italy the causative agent of community-acquired pneumonia is 
isolated only in a small fraction (<35%) of hospitalization cases.10
Nonetheless, further studies are necessary to confirm the 
validity of the proposed model.
Irrespective of the validity of the assumptions underlying the 
model, our study also found that the hospitalization rates for 
pneumococcal pneumonia increase in our age strata, and are 
more than 15-fold higher in older patients, with a decreasing 
temporal trend in all age groups from 2005 through 2012.
The higher risk with age is a well known and documented 
phenomenon that has been attributed to immunosenescence 
and the increasing frequency of co-morbidities in the elderly, 
suggesting that the policy strategies for implementing vaccination 
in adults by age could differ by geographic area according to local 
demography and epidemiology.15-17 Notably, our data indicate 
that though pneumococcal pneumonia has been diagnosed in 
all age groups, vaccinating persons ≥65 may be the most cost-
effectiveness public health strategy in our setting.
We also found a slight, though constant, reduction of 
pneumococcal pneumonia cases over time. Several studies 
have found that adults may benefit from extensive childhood 
pneumococcal vaccination through indirect effects.18 In our 
region, the childhood conjugate vaccination for pneumococcal 
was introduced in the regional immunization program and 
actively offered from 2005, with rapidly increasing vaccination 
coverage, so the observed decline among adult populations could 
be attributed to the indirect, or herd, protection provided by 
pneumococcal conjugate vaccines in childhood.6,19 On the other 
hand, a residual role may also be played by the small fraction of 
adults vaccinated with PPV23 vaccine.
Consonant with our findings, a study found an annual 
reduction in hospitalization for pneumonia among adults in 
the United States in the decade after the introduction of PCV7 
in the infant immunization schedule.20 In our study, all-cause 
pneumonia hospitalizations did not decrease over time. Though 
we are not able to elucidate possible determinants for this 
different trend, it can be hypothesized that several behavioral and 
normative factors and confounders (e.g., prevalence of smokers 
in the general population, influenza and influenza vaccination 
coverage, hospital admission thresholds) may be responsible for 
this difference in findings.
It should be noted that our study was not designed specifically 
to assess the impact of the current preventive measures and, in 
this sense, the impossibility of controlling for the previously 
Table 1. estimated hospitalization rates (cases per 100 000 adults) for pneumococcal pneumonia in sicily (2005 through 2012)
2005 2006 2007 2008 2009 2010 2011 2012
Age group
50–54 34.0 28.5 21.5 34.8 21.0 27.0 25.3 28.3
55–59 43.6 37.9 38.9 47.5 51.5 35.8 21.9 23.6
60–64 75.9 53.7 48.6 66.6 58.9 48.9 43.8 23.2
65–69 89.2 93.1 59.2 59.8 59.3 77.4 56.0 66.5
70–74 125.8 122.1 93.1 95.0 122.1 138.5 93.3 52.1
75–79 252.3 219.0 184.7 224.8 161.8 210.4 215.8 178.2
80 or more 509.7 475.2 344.2 306.9 397.4 451.4 349.2 395.7
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cited and other potential confounding factors may well be a 
major limitation of our study, as well as other retrospective 
studies. Finally, our model should be considered conservative 
for invasive pneumococcal diseases because it overlooks other 
invasive sites different from pneumonia and, including only 
hospitalized cases of pneumococcal pneumonia, enabled us 
to estimate severe cases, excluding information on mild cases 
treated in out-patient settings.
Despite these limitations, our model provides data usable 
to construct suitable decisional models for the decision-makers 
and could allow to the responsibles of healthcare facilities to 
assess the budget impact if they hypothesize to offer vaccination 
for pneumococcal disease to certain cohorts of subjects 
aged 50 y or older. In our area, the relatively high estimated 
hospitalization rates among adults aged ≥65 y highlight the 
need to enhance active surveillance, and implement effective 
preventive strategies (e.g., vaccination) tailored for these age 
groups.
Material and Methods
This study evaluated the administrative and clinical data 
of patients resident in Sicily, a large Italian region of about 
5 000 000 residents. All data included in the analyses were 
obtained by the Region of Sicily’s Health Commission, which 
routinely collects hospital discharge records (HDR) from all 
of the region’s hospitals. The Regional Hospital Discharge 
Database, which was established in 1994, collects complete 
data on hospitalizations from both public and private hospitals. 
Each HDR includes demographic information (birthplace, 
residence, gender, and date of birth), admission and 
discharge dates, discharge status (categorized as “discharged/
transferred” or “expired”), and up to 6 discharge diagnoses 
(1 principal and 5 secondary diagnoses) coded according 
to International Classification of Disease, Ninth Revision, 
Clinical Modification (ICD-9 CM).
All patients aged 50 y or older and hospitalized in acute-
care hospitals from 2005 to 2012 with at least one ICD-9 CM 
code among those reported in Figure 1, either as principal or 
secondary diagnosis, were used for estimating hospitalization 
rates due to pneumococcal pneumonia.
Hospitalization of Sicilian residents that occurred outside 
the region was also included in the analysis, while multiple 
hospitalizations due to transfers were combined. Admissions 
for transferred patients were followed until discharge or death.
The study was approved by the Institutional Review Board 
of the AOUP “P. Giaccone” of Palermo, Italy.
Model design
As shown in Figure 1, considering that pneumococcal 
pneumonia (PP1; n = 1943) represented 28.4% of bacterial 
pneumonia due to specified agents (SBP; n = 6846), the same 
percentage was expected to be attributable to pneumococcal 
among bacterial pneumonia due to unspecified agents (UBP; 
n = 6480). Thus, the total number of unspecified bacterial 
pneumonia due to S. pneumoniae (PP2; estimated n = 1839) 
was obtained with the following equation:
 (1)
Since pneumococcal pneumonia (PP1+PP2; n = 3782) 
accounted for 22.8% of all specified pneumonia (SP; n = 
16 561), the same percentage was expected to be attributable 
to pneumococcal among all unspecified pneumonia (UP; n = 
55 869). Thus, the fraction of unspecified pneumonia due to 
S. pneumoniae (PP3; estimated n = 12 759) was calculated with 
the following equation:
 (2)
Finally, the estimated hospitalized pneumococcal 
pneumonia was calculated as the sum of pneumococcal 
pneumonia (PP1) and the fractions of unspecified bacterial 
pneumonia and unspecified pneumonia due to S. pneumoniae 
(PP2 and PP3, respectively).
Statistical analysis
Absolute and relative frequencies with 95% confidence 
intervals (CI) were calculated for qualitative variables, while 
quantitative variables were summarized as mean ± standard 
deviation when normally distributed or otherwise as median 
(interquartile range). Data normality was verified by the 
Shapiro–Wilk test for normality. The data trends were 
evaluated by using the chi-square test for trends.
Annual total and age-specific hospitalization rates (5-y 
strata) (2005–2012) were calculated by dividing the annual 
number of hospitalizations for the resident Sicilian population 
aged over 49 y on the 1st of the following year (data 
obtained from ISTAT).21 Rates are expressed as hospitalized 
pneumococcal pneumonia/100 000 per year, with a 95% CI. 
A two-tailed P value of <0.05 was considered statistically 
significant. All data were analyzed with the R statistical 
software package.
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